Sage Journals: Discover world-class research

Abstract

Objective

Prevention of exit-site infection (ESI) is of paramount importance to peritoneal dialysis (PD) patients. The aim of this study was to evaluate the effectiveness of chlorhexidine in the prevention of ESI in incident PD patients compared with mupirocin.

Methods

This retrospective, pre-test/post-test observational study included all incident PD patients at Singapore General Hospital from 2012 to 2015. Patients received daily topical exit-site application of either mupirocin (2012 – 2013) or chlorhexidine (2014 – 2015) in addition to routine exit-site cleaning with 10% povidone-iodine. The primary outcome was ESI rate during the 2 time periods. Secondary outcomes were peritonitis rate, times to first ESI and peritonitis, hospitalization rate, and infection-related catheter removal. Event rates were analyzed using Poisson regression, and infection-free survival was estimated using Kaplan-Meier and Cox regression survival analyses.

Results

The study included 162 patients in the mupirocin period (follow-up 141.5 patient-years) and 175 patients in the chlorhexidine period (follow-up 136.9 patient-years). Compared with mupirocin-treated patients, chlorhexidine-treated patients experienced more frequent ESIs (0.22 vs 0.12 episodes/patient-year, p = 0.048), although this was no longer statistically significant following multivariable analysis (incidence rate ratio [IRR] 1.78, 95% confidence interval [CI] 0.98 – 3.26, p = 0.06). No significant differences were observed between the 2 groups with respect to time to first ESI (p = 0.10), peritonitis rate (p = 0.95), time to first peritonitis (p = 0.60), hospitalization rate (p = 0.21) or catheter removal rate (0.03 vs 0.04/patient-year, p = 0.56).

Conclusions

Topical exit-site application of chlorhexidine cream was associated with a borderline significant, higher rate of ESI in incident PD patients compared with mupirocin cream.

Keywords

Antibiotic prophylaxis anti-infective agents catheter-related infections chlorhexidine exit-site infection mupirocin peritoneal dialysis peritonitis prophylaxis topical antibiotics treatment outcome

Get full access to this article

View all access options for this article.

References

Kavanagh

, Prescott

G.J.

, Mactier

R.A.

Peritoneal dialysis-associated peritonitis in Scotland (1999-2002).

Nephrol Dial Transplant 2004; 19(10): 2584–91.

Woodrow

, Turney

J.H.

, Brownjohn

A.M.

Technique failure in peritoneal dialysis and its impact on patient survival.

Perit Dial Int 1997; 17(4): 360–4.

Fried

L.F.

, Bernardini

, Johnston

J.R.

, Piraino

Peritonitis influences mortality in peritoneal dialysis patients.

J Am Soc Nephrol 1996; 7(10): 2176–82.

Pérez Fontan

, Rodríguez-Carmona

, García-Naveiro

, Rosales

, Villaverde

, Valdés

Peritonitis-related mortality in patients undergoing chronic peritoneal dialysis.

Perit Dial Int 2005; 25(3): 274–84.

van Diepen

A.T.N.

, Tomlinson

G.A.

, Jassal

S.V.

The association between exit-site infection and subsequent peritonitis among peritoneal dialysis patients.

Clin J Am Soc Nephrol 2012; 7(8): 1266–71.

Mehrotra

, Singh

Peritoneal dialysis-associated peritonitis with simultaneous exit-site infection.

Clin J Am Soc Nephrol 2013; 8(1): 126–30.

Gupta

, Bernardini

, Piraino

Peritonitis associated with exit-site and tunnel infections.

Am J Kidney Dis 1996; 28(3): 415–9.

Bernardini

, Piraino

, Holley

, Johnston

J.R.

, Lutes

A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin.

Am J Kidney Dis 1996; 27(5): 695–700.

Bernardini

Randomized, double-blind trial of antibiotic exit-site cream for prevention of exit-site infection in peritoneal dialysis patients.

J Am Soc Nephrol 2005; 16(2): 539–45.

10.

Lim

C.T.-S.

, Wong

K-S

, Foo

M.W.-Y.

The impact of topical mupirocin on peritoneal dialysis infection in Singapore General Hospital.

Nephrol Dial Transplant 2005; 20(10): 2202–6.

11.

Thodis

, Bhaskaran

, Pasadakis

, Bargman

J.M.

, Vas

S.I.

, Oreopoulos

D.G.

Decrease in Staphylococcus aureus exit-site infections and peritonitis in CAPD patients by local application of mupirocin ointment at the catheter exit site.

Perit Dial Int 1998; 18(3): 261–70.

12.

P.K.

, Szeto

C-C

, Piraino

, de Arteaga

, Fan

, Figueiredo

A.E.

ISPD peritonitis recommendations: 2016 update on prevention and treatment.

Perit Dial Int 2016; 36(5): 481–508.

13.

Annigeri

, Conly

, Vas

, Dedier

, Prakashan

K.P.

, Bargman

J.M.

Emergence of mupirocin-resistant Staphylococcus aureus in chronic peritoneal dialysis patients using mupirocin prophylaxis to prevent exit-site infection.

Perit Dial Int 2001; 21(6): 554–9.

14.

Babu

, Rekasius

, Parada

J.P.

, Schreckenberger

, Challapalli

Mupirocin resistance among methicillin-resistant Staphylococcus aureus-colonized patients at admission to a tertiary care medical center.

J Clin Microbiol 2009; 47(7): 2279–80.

15.

Patel

J.B.

, Gorwitz

R.J.

, Jernigan

J.A.

Mupirocin resistance.

Clin Infect Dis 2009; 49(6): 935–41.

16.

Pérez-Fontán

, Rosales

, Rodríguez-Carmona

, Falcón

T.G.

, Valdés

Mupirocin resistance after long-term use for Staphylococcus aureus colonization in patients undergoing chronic peritoneal dialysis.

Am J Kidney Dis 2002; 39(2): 337–41.

17.

, Tu

, Xu

Mupirocin for preventing exit-site infection and peritonitis in patients undergoing peritoneal dialysis.

Nephrol Dial Transplant 2010; 25(2): 587–92.

18.

Nessim

S.J.

, Jassal

S.V.

Gentamicin-resistant infections in peritoneal dialysis patients using topical gentamicin exit-site prophylaxis: a report of two cases.

Perit Dial Int 2012; 32(3): 339–41.

19.

Landry

D.L.

, Braden

G.L.

, Gobeille

S.L.

, Haessler

S.D.

, Vaidya

C.K.

, Sweet

S.J.

Emergence of gentamicin-resistant bacteremia in hemodialysis patients receiving gentamicin lock catheter prophylaxis.

Clin J Am Soc Nephrol 2010; 5(10): 1799–804.

20.

McDonnell

, Russell

A.D.

Antiseptics and disinfectants: activity, action, and resistance.

Clin Microbiol Rev 1999; 12(1): 147–79.

21.

Russell

A.D.

, Day

M.J.

Antibacterial activity of chlorhexidine.

J Hosp Infect 1993; 25(4): 229–38.

22.

Weinstein

R.A.

, Milstone

A.M.

, Passaretti

C.L.

, Perl

T.M.

Chlorhexidine: expanding the armamentarium for infection control and prevention.

Clin Infect Dis 2008; 46(2): 274–81.

23.

Lowbury

E.J.

, Lilly

H.A.

Use of 4 per cent chlorhexidine detergent solution (Hibiscrub) and other methods of skin disinfection.

Br Med J 1973; 1(5852): 510–5.

24.

Günther

, Kaiser

S.J.

, Fries

, Frank

, Mutters

N.T.

Susceptibility of multi-drug resistant clinical pathogens to a chlorhexidine formulation.

J Prev Med Hyg 2015; 56(4): E176–9.

25.

Safdar

, O'Horo

J.C.

, Ghufran

, Bearden

, Didier

M.E.

, Chateau

Chlorhexidine-impregnated dressing for prevention of catheter-related bloodstream infection: a meta-analysis.

Crit Care Med 2014; 42(7): 1703–13.

26.

Hon

P.Y.

, Koh

T.H.

, Tan

T.Y.

, Krishnan

, Leong

J.W.-Y

, Jureen

Changing molecular epidemiology and high rates of mupirocin resistance among meticillin-resistant Staphylococcus aureus in Singaporean hospitals.

J Glob Antimicrob Resist 2014; 2(1): 53–5.

27.

Szeto

C.C.

, Li

P.K.

, Johnson

D.W.

, Bernardini

, Dong

, Figueiredo

ISPD catheter-related infections recommendations: 2017 update.

Perit Dial Int 2017. doi:10.3747/pdi.2016.00120 [Epub ahead of print.]

28.

Fine

J.P.

, Gray

R.J.

A proportional hazards model for the subdistribution of a competing risk.

J Am Stat Assoc 1999; 94(446): 496.

29.

Crawford

, Chu

Can 2% chlorhexidine aqueous solution provide better infection control in PD exit-site care when compared with 10% povidone-iodine: a single unit experience.

Ren Soc Australas J 2014; 10(3): 116.

30.

Jones

L.L.

, Tweedy

, Warady

B.A.

The impact of exit-site care and catheter design on the incidence of catheter-related infections.

Adv Perit Dial Conf Perit Dial 1995; 11: 302–5.

31.

Chambers

S.T.

, Sanders

, Patton

W.N.

, Ganly

, Birch

, Crump

J.A.

Reduction of exit-site infections of tunnelled intravascular catheters among neutropenic patients by sustained-release chlorhexidine dressings: results from a prospective randomized controlled trial.

J Hosp Infect 2005; 61(1): 53–61.

32.

Paglialonga

, Consolo

, Biasuzzi

, Assomou

, Gattarello

, Patricelli

M.G.

Reduction in catheter-related infections after switching from povidone-iodine to chlorhexidine for the exit-site care of tunneled central venous catheters in children on hemodialysis: chlorhexidine for CVC in children on HD.

Hemodial Int 2014; 18: S13–8.

33.

Vali

, Davies

S.E.

, Lai

L.L.G.

, Dave

, Amyes

S.G.B.

Frequency of biocide resistance genes, antibiotic resistance and the effect of chlorhexidine exposure on clinical methicillin-resistant Staphylococcus aureus isolates.

J Antimicrob Chemother 2008; 61(3): 524–32.

34.

Block

, Furman

Association between intensity of chlorhexidine use and micro-organisms of reduced susceptibility in a hospital environment.

J Hosp Infect 2002; 51(3): 201–6.

35.

Horner

, Mawer

, Wilcox

Reduced susceptibility to chlorhexidine in Staphylococci: is it increasing and does it matter?

J Antimicrob Chemother 2012; 67(11): 2547–59.

36.

Russell

A.D.

Introduction of biocides into clinical practice and the impact on antibiotic-resistant bacteria.

J Appl Microbiol 2002; 92(Suppl): 121S–35S.

37.

Senior

Some observations on the formulation and properties of chlorhexidine.

J Soc Cosmet Chem 1973; 24: 259–78.

Comparison of Topical Chlorhexidine and Mupirocin for the Prevention of Exit-Site Infection in Incident Peritoneal Dialysis Patients

Abstract

Objective

Methods

Results

Conclusions

Keywords

Get full access to this article

References